The Russian biotech company TheraMAB, a portfolio company of the Bioprocess Capital Venture fund and partially owned by RVC, has launched clinical phase Ib trials of the drug TAB08 for the treatment of cancerous diseases. The new phase aims to test the drug tolerability and assess likely response of the oncological patient's organism.
The drug is unique in that it influences the original cause of the disease by normalizing the functional balance of different immune cells, while other drugs only deal with the effects of diseases. TAB08 is a humanized monoclonal antibody of class IgG4 binding the costimulatory receptor (CB28), specific for human T-lymphocytes.
The drug has already successfully passed the clinical trials of the first phase and proved its safety and good tolerability for healthy volunteers and patients with autoimmune diseases.
TheraMAB was duly authorized to clinically test this phase of TAB08 on November 15, 2016 Full name of the test phase: "Study of the 1st phase with multiple administration and escalation of doses of TAB08 in patients with solid tumors of late stages."
RVC is a governmental fund of funds, the Institute of Development of the Russian Federation. The main objectives of RVC: stimulating the creation of Russia's venture capital industry and execution of functions of the Project Office of the National Technology Initiative (NTI). The authorized capital of RVC is more than 30 billion rubles. One hundred per cent of the RVC capital belongs to the Russian Federation represented by the Federal Agency for Management of State Property of the Russian Federation (Federal Property Management Agency). The total number of funds formed by RVC JSC has reached 22, their total size is 33.8 billion rubles. The share of RVC is 20.6 billion rubles. The number of innovative companies approved for investment by RVC funds has reached 203 The aggregate volume of invested funds is 17.6 billion rubles.
About Bioprocess Capital Ventures CE VF
Venture fund Bioprocess Capital Ventures, partially owned by Russian Venture Company OJSC and managed by Bioprocess Capital Partners, invests exclusively in innovative projects that create new products and technologies in the field of biotechnology, fine chemicals and telecommunications. The choice of priority areas for investment is due to the competence of the BCF management team, who has extensive experience in these areas. Currently, the Fund's portfolio contains seven companies, four of which have already become residents of the cluster of biomedical technologies and one is a resident of the cluster of nuclear technologies of the Skolkovo Innovation Center.
About TheraMAB LLC TheraMAB LLC is a Russian biotechnology company financed by the venture fund Bioprocess Capital Ventures and partially owned by Russian Venture Company JSC. TheraMAB LLC was organized in August 2009 with the help of the investment fund Bioprocess Capital Ventures and the German biotechnology company TheramAB GmbH. The project aims to develop an original drug TAB08 based on a monoclonal antibody that will effectively monitor the immune balance by activating and proliferating functionally active regulatory T cells without general immunosuppression. The drug is planned to be used in the treatment of acute and chronic forms of rheumatoid arthritis and some forms of leukemia.